Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05511155
Other study ID # 64-SBKAEK
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2022
Est. completion date September 30, 2022

Study information

Verified date September 2022
Source Aksaray University Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Headache is one of the common causes of emergency department admissions and constitutes approximately 2%. Although the exact mechanism is not clear, It is known that high-flow oxygen therapy is effective in headache treatment. There are limited studies related to the use of oxygen therapy in headaches and its derivatives in the literature. In this study, the investigators aimed to compare the high and medium flow oxygen therapies with placebo in primary headache disorders.


Description:

Four different treatment methods were determined; 1) high-flow oxygen (15lt/min oxygen), 2) medium-flow oxygen (8lt/min oxygen), 3) high-flow room air as placebo (15 lt/min room air), 4) medium-flow room air as placebo (8 lt/min room air). All four treatment methods will be applied to all patients included in the study. One of the four treatments will be randomly applied at each separate ED admission with a gap of 1 week or more in between. This randomization will be performed by a computer at the time of admission. A study nurse will administer the patient's therapy according to the computer's current decision for 15 minutes. Patients and treating physicians will be blinded to the selected therapy. After 15 minutes of the end of treatment (at the 30th minute of the start of treatment), the treating physician will ask patients if they need rescue analgesia and analgesia will be administered if necessary. Additional analgesia is at the discretion of the treating physician. Patient data, including demographics, medical history, and findings of a physical examination performed before and after therapy will be recorded by the treating physician.


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date September 30, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - age 18-55 years - frequent attacks of primary headache disorders according to International Headache Society (IHS) criteria Exclusion Criteria: - secondary headache disorders - oxygen-dependent chronic illnesses such as chronic obstructive pulmonary disease - a history of cerebrovascular disease - pregnancy - active smokers or living with a smoker.

Study Design


Intervention

Other:
Oxygen therapy
Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.

Locations

Country Name City State
Turkey Aksaray University Aksaray Training and Research Hospital Aksaray

Sponsors (1)

Lead Sponsor Collaborator
Aksaray University Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Friedman BW, Grosberg BM. Diagnosis and management of the primary headache disorders in the emergency department setting. Emerg Med Clin North Am. 2009 Feb;27(1):71-87, viii. doi: 10.1016/j.emc.2008.09.005. Review. — View Citation

Mo H, Chung SJ, Rozen TD, Cho SJ. Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders. J Clin Neurol. 2022 May;18(3):271-279. doi: 10.3988/jcn.2022.18.3.271. Review. — View Citation

Petersen AS, Barloese MC, Lund NL, Jensen RH. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2017 Mar;37(3):214-224. doi: 10.1177/0333102416637817. Epub 2016 Jul 11. — View Citation

Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D'Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015 Feb;35(2):118-31. doi: 10.1177/0333102414550416. Epub 2014 Sep 22. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary visual analog scale score primary endpoint is the relative reduction in visual analog scale (a psychometric response scale) score in the placebo versus oxygen group to determine whether there was a difference between the high-flow and mid-flow therapies. visual analog scale scaled from 0-100 points with 0 meaning "no pain" and 100 points meaning "worst possible pain". 0-60 minutes
Secondary rescue analgesia rescue analgesia (yes/no) 30 th minutes
Secondary length of stay length of stay in the emergency department (time in minutes) 0-300 minutes
Secondary duration of a pain duration of a pain attack (time in minutes) 0-300 minutes
Secondary readmission readmission to the emergency department within 7 days (yes/no) 0-7 days
See also
  Status Clinical Trial Phase
Completed NCT00449787 - Comparing Naproxen to Sumatriptan for Emergency Headache Patients Phase 4
Recruiting NCT04080258 - Effectiveness of Osteopathic Manipulative Therapy in Paediatric Patients, With High Frequency Headache. N/A
Active, not recruiting NCT04178252 - Effectiveness of Eye Mask and Noise Reduction Headset in Primary Headache N/A
Not yet recruiting NCT05057533 - Primary Headaches and Irritable Bowel Syndrome.
Enrolling by invitation NCT05760625 - Gender Differences and Features of the Clinical Course of Primary Headaches
Withdrawn NCT05337930 - Feasibility of a Developmentally-tailored Mobile App for Tracking Mood and Pain in Children With Migraine N/A
Active, not recruiting NCT05023460 - Treatment of Chronic Cluster Headache With TENS and ONS N/A
Recruiting NCT03499392 - Primary Headache and Psychological Factors, Mental Functioning and Attachment Modalities. N/A